Announcement PDF ASX Announcement 18 November 2024 Microba receives $6 million R&D Tax Incentive Refund • $6 million R&D Tax Incentive Refund received for Research & Development Activities conducted during FY24 • The FY24 R&D Tax Incentive adds to Microba’s strong financial position of $16.4 million in Cash or equivalents reported at the end of Q1 FY25 Microba Life Sciences Limited (ASX: MAP) (“Microba”), a company at the forefront of microbiome diagnostics & therapeutics, is pleased to announce that the Company has received a $6,019,829 Research & Development (R&D) Tax Incentive refund relating to R&D activities completed in the 2023/2024 financial year. The Australian Government’s R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities. In addition to Microba’s Australian R&D activities being eligible for the R&D Tax Incentive, Microba has also received four separate Advanced Overseas Findings from AusIndustry, which pre-approve eligible overseas expenditure for research and development activities across its Inflammatory Bowel Disease (IBD) and Autoimmune Diseases therapeutic programs. These four Advanced Overseas Findings cover total eligible overseas expenditure across FY22, FY23, FY24 and FY25. Microba’s Chief Executive Officer, Dr. Luke Reid, expressed his appreciation for the receipt of the R&D Tax Incentive, stating, “We strongly value the Australian Government’s continued support through the R&D Tax Incentive Program. This initiative is instrumental in enabling Microba to advance our pipeline of clinical-stage therapeutics and innovative diagnostic gastrointestinal tests. As we progress these programs, we are confident in their potential to significantly improve the health and wellbeing of Australians.” View this announcement on our Investor Hub: https://ir.microba.com/link/oPBzQP This announcement has been authorised for release by the Chair and Chief Executive Officer. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com Investor / Media Relations investor@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621